Reviva reports FY2024 net loss $29.9M, cash $13.5M; positive OLE data sustained

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss $29.9M ($0.90/shr) vs $39.3M ($1.65/shr) in 2023; cash $13.5M at Dec 31, 2024 vs $23.4M.
OLE trial: pooled PANSS total score decreased 18.6 points (p≤0.0001) at 1 year; well tolerated with no single side effect >5%.
Registrational Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia expected to initiate mid-2025.
Full OLE data including vocal and blood biomarkers due Q2 2025; NDA submission targeted Q4 2026.
Completed public follow-on offering with gross proceeds of ~$18.0M in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.